Biotechs are saving the world from superbugs. Can they also save themselves?

The world is now heavily reliant on small- and medium-sized enterprises (SMEs) to bring life-saving new antibiotics and antifungals to market. Accounting for 75% of all late-stage antibiotics and antifungals in development, they are pivotal in driving new antimicrobial innovation. Yet despite this, these smaller companies often face funding shortfalls and bankruptcy, leaving promising new drugs stranded on the lab bench. This report identifies how a crop of SMEs are finding new ways to survive and bring their life-saving medicines successfully through the pipeline.